Objective: To compare cerebral vasoreactivity, a measure of cerebrovascular endothelial function, between treated, virally suppressed HIV-infected individuals and HIVuninfected controls and to evaluate the effect of HIV-specific factors on cerebral vasoreactivity.
population [8] . The mechanisms underlying increased cerebrovascular risk in HIV infection, however, have not been investigated. Cerebrovascular function in individuals with treated, virally suppressed chronic HIV infection is unknown, including whether it is impaired compared with HIV-uninfected individuals.
Cerebral vasoreactivity is a measure of cerebrovascular endothelial function associated with both small vessel and severe large artery cerebrovascular injury [9] [10] [11] [12] [13] [14] . Measurement of cerebral vasoreactivity with transcranial Doppler (TCD) ultrasound is noninvasive, cost-effective and has excellent temporal resolution. A vasodilatory response to inhaled carbon dioxide (CO 2 ) and vasoconstriction to hyperventilation, denoted by an increase and decrease in mean blood flow velocity of the cerebral arteries, respectively, is one method of assessing cerebral vasoreactivity. Changes in cerebral vasoreactivity over time and in response to interventions aimed at improving cerebrovascular function can be readily monitored. For example, cerebral vasoreactivity has been shown to improve with interventions that reduce cerebrovascular risk, including statin use and exercise [15] [16] [17] .
The primary goal of the UNderstanding Cerebral VasoReactivity in HIV infection (UNCoVeR) study was to compare cerebral vasoreactivity between treated, virally suppressed HIV-infected individuals and uninfected controls and to evaluate the effect of HIV-specific factors on cerebral vasoreactivity.
Methods

Study population
We performed a cross-sectional study of a convenience sample of participants from SCOPE [18] (the Study of the Consequences of the Protease Inhibitor Era), a contemporary cohort of over 2000 HIV-infected individuals and uninfected controls followed prospectively at San Francisco General Hospital. Participants involved in a parent study evaluating cardiovascular health in HIV infection in SCOPE were contacted to gauge interest in participation in a sub-study focused on cerebrovascular risk. Original recruitment for the parent study occurred at routine SCOPE visits, where participants received information regarding the cardiovascular study and, if interested, contacted the study for additional details. Demographically matched uninfected controls were recruited for the parent study through referrals of friends and acquaintances of HIV-infected participants and were tested for HIV prior to entry. Flyers were also posted around the hospital and outpatient clinics advertising the parent study. All participants were at least 18 years of age and willing to abstain from caffeine, tobacco, alcohol or other substance use for 12 h prior to the study. The study was approved by the University of California, San Francisco Committee on Human Research.
All HIV-infected participants were on a stable antiretroviral therapy (ART) regimen with undetectable plasma HIV RNA (<40 copies/ml) for a minimum of 24 weeks prior to the study. Exclusion criteria included a history of stroke or transient ischemic attack, central nervous system (CNS) infection or traumatic brain injury in the 3 months before the study; a history of intracranial vasculitis or arteriopathy due to causes other than HIV or traditional vascular disease (e.g., primary CNS vasculitis); use of immune modulatory agents in the 3 months before the study; absent temporal acoustic windows; a history of an untreated cerebral aneurysm or other vascular malformation, severe chronic obstructive pulmonary disease, unstable angina, recent myocardial infarction or other conditions that precluded cerebral vasoreactivity testing.
Cerebral vasoreactivity
We assessed cerebral vasoreactivity with the CO 2 challenge test [19] . TCD was used to measure alterations in middle cerebral artery (MCA) mean blood flow velocity in response to changes in end-tidal CO 2 (ETCO 2 ). A single vascular technologist trained in the TCD CO 2 challenge test and blinded to HIV status performed all studies to minimize interrater variability. A Sonara Digital TCD machine (Natus Medical, San Carlos, California, USA) was used for all studies. The MCA signal was identified through a transtemporal approach using standard methodology [20, 21] . We recorded mean blood flow velocities at rest, during inhalation of a 6% CO 2 gas mixture and during mild hyperventilation.
The primary cerebral vasoreactivity outcome was cerebral vasoreactivity in response to hypercapnia (cerebral VR hyper ), defined as the percentage change in mean flow velocity from baseline to induced hypercapnia per unit change in ETCO 2 . As a secondary outcome, we also evaluated cerebral vasoreactivity in response to the full range of hyper and hypocapnia (cerebral VR hyper þ hypo ), calculated as the percentage change in mean flow velocity from hypercapnia to hypocapnia per unit change in ETCO 2 .
We performed repeat cerebral vasoreactivity testing within 1 month of the first procedure to assess reproducibility in five participants. For the repeat study, participants were scheduled at approximately the same time of day as the first procedure to minimize diurnal variability. Because cerebral vasoreactivity for the left and right sides were highly correlated, we compared a single value representing the mean cerebral vasoreactivity from the left and right sides between the first and second visits. We calculated the intraclass correlation coefficient (ICC) after adjusting for the change in mean arterial pressure with induced hypercapnia. We found a strong correlation between cerebral vasoreactivity from the first and second visits, although the large confidence intervals reflect the small number of repeated studies performed (ICC for cerebral VR hyper of 0.80, 95% CI 0.30-0.97; ICC for cerebral VR hyper þ hypo of 0.93, 95% CI 0.65-0.99).
Vascular risk factors, substance use and other covariates
Prior to the TCD study, we collected data on comorbidities and other covariates that could potentially confound or mediate the association between HIV infection and cerebral vasoreactivity, including traditional vascular risk factors (defined by self-report of prior diagnosis by a medical provider with or without current use of antihypertensive, antidiabetic or lipid-lowering therapy); antiplatelet and statin use; current smoking, alcohol and substance use; and a history of migraines and sleep apnea. HIV-specific characteristics, including duration of HIV infection and viral suppression, ART use by class, most recent and nadir CD4 þ cell count, were also obtained. These data were supplemented and/or confirmed by available information through the parent cardiovascular study and review of electronic medical records.
Statistical analysis
We compared demographic and clinical characteristics between HIV-infected and uninfected participants using t-test, Chi-square test or Fisher's exact test. We used mixed effects linear regression models to determine the association between HIV and cerebral vasoreactivity and between HIV-specific factors and cerebral vasoreactivity. Because cerebral vasoreactivity is measured on the left and right sides, we included a random person effect to account for within-person correlation. All multivariable models were adjusted for age and race. In the models of HIV-infected individuals and uninfected controls, we included clinically relevant covariates of a-priori interest (e.g. hypertension, diabetes mellitus, statin use) and other covariates chosen by forward stepwise selection. To maximize parsimony in the HIV-only analyses (given fewer observations), only covariates identified through forward stepwise selection were included. P values were two-sided with 0.05 considered statistically significant. Statistical analyses were performed using Stata (StataCorp 2012. Stata Statistical Software: Release 12; Stata Corporation, College Station, Texas, USA).
Results
Study enrolment
We enrolled 100 individuals between January and June 2014 who underwent the TCD CO 2 challenge. Of these 100 individuals, one participant terminated the study early due to discomfort from breathing into the mouthpiece. In one HIV-infected participant, an acoustic temporal window on neither the left nor right sides could be located. In one control participant, we did not observe an adequate rise in ETCO 2 following inhalation of the CO 2 gas mixture, which was hypothesized to be from a poor seal around the mouthpiece due to a preexisting neurological illness. In four participants (three HIVinfected and one control), cerebral vasoreactivity results were excluded because the expected rise or fall in mean blood flow velocities during inhalation of CO 2 or mild hyperventilation was not observed. In sum, the results from 93 participants were included in the study (65 HIVinfected and 28 uninfected control participants), on whom 175 total (87 left-sided, 88 right-sided) measurements were obtained.
Baseline demographic and clinical characteristics
Demographic and clinical characteristics of the 93 participants are included in Table 1 .
HIV-infected participants were older than uninfected controls, although this did not reach statistical significance. Most participants were men, while 26% of HIVinfected participants were nonwhite compared to 32% of controls. Several vascular risk factors were more common in HIV-infected participants, including hypertension (49 versus 29%, P ¼ 0.065), dyslipidemia (57 versus 21%, P ¼ 0.002) and diabetes mellitus (12 versus 0%, P ¼ 0.10). Statin and aspirin use were also more common among HIV-infected participants. More uninfected controls were current alcohol users, while marijuana use was more common among HIV-infected participants. Among the HIV-infected cohort, the mean CD4 þ cell count was 596 cells/ml, while the mean nadir CD4 þ cell count was 242 cells/ml. The mean duration of known HIV seropositivity was 20.2 years, and mean duration of viral suppression was 7.8 years. Nearly all participants were on an ART regimen that contained at least one nucleoside reverse transcriptase inhibitor (NRTI) and 32% were on abacavir, while over half were on a nonnucleoside reverse transcriptase inhibitor (NNRTI) compared to 42% on a protease inhibitor and 34% on an integrase inhibitor.
Baseline mean blood flow velocities
Baseline mean blood flow velocity on the right and left sides for HIV-infected individuals were 52 and 53 cm/s, respectively, compared to 51 cm/s bilaterally for uninfected controls (P ¼ 0.65 for the right side, P ¼ 0.37 for the left side). As expected, intra-participant right and leftsided cerebral VR hyper and cerebral VR hyper þ hypo measurements were strongly correlated [Pearson correlation coefficients 0.85 (P < 0.001) and 0.93 (P < 0.001), respectively].
Difference in cerebral vasoreactivity by HIV status
Cerebral VR hyper was reduced in HIV-infected individuals compared to uninfected controls (cerebral VR hyper 3.23%, 95% CI 2.98-3.47% compared with 3.81%, 95% CI 3.44-4.18%, P ¼ 0.010) ( Table 2 ). After adjustment for age, race, diabetes mellitus, hypertension, statin use, aspirin use, alcohol consumption and methamphetamine use, HIV infection was independently associated with lower cerebral vasoreactivity (-0.86%, 95% CI -1.30% to -0.42%, P < 0.001) ( Fig. 1 , Table 2 ). Diabetes mellitus and nonwhite race were also independent predictors of lower cerebral VR hyper , as was methamphetamine use ( Table 2) . Each additional drink per day was associated with an increase in cerebral VR hyper . In the multivariate model of cerebral VR hyper , we observed an interaction between statin use and HIV infection. Statin use among those with HIV infection was associated with an improvement in cerebral VR hyper , while it had no statistically significant impact on cerebral VR hyper among uninfected controls ( Table 2) . We observed a trend toward an association between hepatitis C infection and cerebral VR hyper in a univariate model ( Table 2) but not in the multivariate model. To check for stability of the final multivariate model, we performed adjusted models excluding several variables that affected a relatively small number of participants (e.g. diabetes mellitus, methamphetamine and statin use). In these simpler models, the main effect of HIV infection on cerebral vasoreactivity was highly comparable to the full model.
In a secondary analysis, unadjusted cerebral VR hyper þ hypo was lower in HIV-infected individuals compared to uninfected controls, although confidence intervals were too wide to rule out no difference in cerebral VR hyper þ hypo by HIV status (2.23%, 95% CI 2.09-2.39% compared with 2.44%, 95% CI 2.21-2.67%, P ¼ 0.15) ( Table 3 ). After adjusting for age, race, diabetes mellitus, hypertension, statin use, aspirin use, alcohol consumption, and methamphetamine use, HIV infection was independently associated with a reduction in cerebral VR hyper þ hypo (-0.30%, 95% CI -0.56% to -0.03%, P ¼ 0.030) ( Fig. 1, Table 3 ). In the multivariate model, statin use was strongly associated with an increase in cerebral VR hyper þ hypo (þ0.42%, 95% CI þ0.13% to þ0.71%, P ¼ 0.004) as was alcohol use (þ0.19% for each additional drink per day, 95% CI þ0.04% to þ0.33%, 48 AIDS 2016, Vol 30 No 1 P ¼ 0.012), while diabetes mellitus was associated with a reduction in cerebral VR hyper þ hypo (-0.46%, 95% CI -0.91% to -0.01%, P ¼ 0.047) ( Table 3) .
Risk factors for impaired cerebral vasoreactivity among the HIV-infected cohort
In a multivariate model restricted to HIV-infected individuals, nonwhite race and diabetes mellitus were associated with lower cerebral VR hyper , while statin use predicted higher cerebral VR hyper . There was a trend toward an association between longer duration of viral suppression and higher cerebral VR hyper (Table 4 ). We did not find a statistically significant effect of most recent or nadir CD4 þ cell count, duration of HIV infection or ART class on cerebral VR hyper . In a multivariate model of the secondary outcome, cerebral VR hyper þ hypo , a CD4 þ cell count greater than 500 cells/ml (þ0.33%, 95% CI þ0.03% to þ0.62%, P ¼ 0.032) and longer mean duration of viral suppression (þ0.04% for each additional year of suppression, 95% CI -0.001% to þ0.08%, P ¼ 0.053) were associated with higher cerebral VR hyper þ hypo . In an exploratory analysis in which we stratified the HIV-only model by statin use to investigate the effect of HIV-related and other factors (adjusted for age and race) on participants not exposed to statins, longer mean duration of HIV infection was associated with worse cerebral VR hyper (-0.05% for each additional year of infection, 95% CI -0.09% to -0.01%, P ¼ 0.026) among nonstatin users. Current tobacco use also correlated with a reduction in cerebral VR hyper (-0.67%, 95% CI -1.33% to -0.01%, P ¼ 0.045) among nonstatin users.
Discussion
The primary goal of our study was to evaluate the association between well controlled HIV infection and cerebral vasoreactivity, a measure of cerebrovascular function. We found that cerebral vasoreactivity was reduced in treated, virally suppressed HIV-infected individuals independent of traditional vascular risk factors that can impact cerebral vasoreactivity, including hypertension and diabetes mellitus. These results suggest that treated HIV infection may confer additional cerebrovascular risk beyond that explained by comorbid traditional vascular risk factors.
Few studies have been performed investigating cerebral vasoreactivity in HIV-infected individuals. One study from early in the treatment era evaluated cerebral vasoreactivity using acetazolamide as the vasodilatory stimulus in 27 HIV-infected individuals and 10 uninfected controls [22] . immunodeficiency (mean CD4 þ cell count 217 cells/ml) compared to our cohort. Mean cerebral vasoreactivity was statistically significantly lower in the HIV-infected group compared to uninfected controls. However, minimal clinical information, such as ARTuse or comorbid vascular risk factors, was available for comparison.
To our knowledge, this is the first study assessing cerebral vasoreactivity in treated, virally suppressed HIV-infected individuals. Even among individuals with well controlled HIV infection, which increasingly reflects the HIV population with access to ART, we observed reduced cerebral vasoreactivity when compared with demographically matched HIV-uninfected controls. Chronic HIV infection and its long-term inflammatory and immunologic effects may contribute to impaired cerebral vasodilatation at the arteriolar level in response to hypercapnia, which reflects intracranial endothelial dysfunction [23] [24] [25] . While few data are available regarding cerebrovascular endothelial function in HIV infection, findings from this study can be viewed in parallel with results from studies demonstrating systemic endothelial dysfunction, a marker of cardiovascular risk often evaluated with flow-mediated dilatation (FMD) of the brachial artery, in HIV-infected individuals. FMD is impaired in ART-naive HIV-infected individuals, and rapidly improves after initiation of ART [26] . However, even among ART-treated individuals with well controlled HIV infection, systemic endothelial function remains impaired. In participants from the parent study evaluating cardiovascular health in SCOPE from which our cohort was drawn, ART-treated HIV-infected individuals with undetectable HIV viral load had worse endothelial function compared to healthy controls [27] . Persistent systemic endothelial dysfunction in well controlled HIV infection is hypothesized to be due to inflammatory and immune consequences of chronic HIV infection, which do not fully normalize despite virologic suppression and immune reconstitution on ART [28] [29] [30] . HIV 'elite controllers', a unique group of untreated HIV-infected individuals with undetectable viral load who lack the potential confounding effect of ART, also demonstrate increased inflammation, immune activation and atherosclerosis compared to HIV-uninfected controls, even after adjustment for traditional vascular risk factors [31, 32] .
Hyperemic velocity, which reflects microvascular endothelial function, has been correlated with systemic markers of inflammation in HIV-infected individuals [33] . Although we observed a trend toward an association between longer duration of viral suppression and higher cerebral vasoreactivity, markers of immune activation and inflammation, which were not available for this study, would be more informative in future studies. In an exploratory analysis, we stratified the HIV-infected cohort by statin use to examine whether the effect of HIV-specific factors on cerebral vasoreactivity was masked by statin use. Indeed, among HIV-infected nonstatin users, the duration of known HIV infection was associated with diminished cerebral vasoreactivity, independent of age, consistent with the possibility that the accumulation of immunologic and inflammatory consequences of chronic HIV infection over the long-term may drive the development of cerebral endothelial dysfunction in this population.
Statin use was consistently associated with higher cerebral vasoreactivity among HIV-infected individuals. Among their pleiotropic effects, statins improve endothelial function by upregulating expression and activity of endothelial nitric oxide synthase resulting in increased bioavailability of nitric oxide [34] . In individuals with vascular risk factors, prior stroke and impaired cerebrovascular function, statin use may increase cerebral vasoreactivity [15, 35] . However, a statistically significant increase in cerebral vasoreactivity among individuals with preserved cerebrovascular function was not found, which may explain the lack of an observed benefit of statin use on cerebral VR hyper among uninfected controls in our study. The increase in cerebral vasoreactivity demonstrated with statin use argues for a unique benefit of statins among HIV-infected individuals to prevent vascular events, which is being evaluated in an ongoing trial.
Although untreated hypertension, which stimulates cerebrovascular remodelling and endothelial damage [36] , has been linked to reduced cerebral vasoreactivity in the general population [37] [38] [39] [40] , we did not observe a statistically significant association between hypertension and lower cerebral vasoreactivity in our cohort. This may be at least partially accounted for by near universal use of antihypertensive therapy among individuals with hypertension in our cohort. Diabetes mellitus, however, which alters endothelial function and has been correlated with diminished cerebral vasoreactivity [23, 41] , was associated with reduced cerebral vasoreactivity among HIV-infected individuals. HIV-infected individuals are at high risk for diabetes mellitus [42, 43] , an established risk factor for cerebral small vessel disease in the general population. Diabetes mellitus has been identified as a risk factor for worse neurocognitive performance in older HIV-infected individuals [44, 45] . One hypothesis that merits further investigation is whether this association between diabetes mellitus and neurocognitive dysfunction is mediated through impaired cerebral microvascular function.
While heavy alcohol use is a strong independent risk factor for stroke [46] , moderate alcohol intake has been 52 AIDS 2016, Vol 30 No 1 shown to be protective against ischemic stroke and associated with better systemic endothelial function [47, 48] . The majority of individuals who consumed alcohol in our study fell into the category of 'moderate use', defined as up to two drinks per day, which may explain the correlation with higher cerebral vasoreactivity. We included methamphetamine in the forward stepwise selection process to account for differences in cerebral vasoreactivity by HIV status due to discrepant methamphetamine use. However, its effect on cerebral vasoreactivity should be interpreted cautiously given few methamphetamine users in the cohort.
Although age did not affect cerebral vasoreactivity in our study, nonwhite race had a consistently negative impact on cerebral vasoreactivity in both the full cohort and in the HIV-only model. Most studies of cerebral endothelial function have not evaluated differences in cerebral vasoreactivity by race or ethnicity. Based on studies of systemic endothelial function, differences in vascular biology by race/ethnicity may result in more impaired endothelium-dependent and microvascular vasodilatory function in blacks compared to whites, independent of vascular and metabolic risk factors [49, 50] . Although stroke incidence in the general population is strongly related to black race [51] , none of the large cohort studies of cerebrovascular events in HIV-infected individuals have demonstrated nonwhite race as a risk factor for either ischemic or hemorrhagic stroke.
Our study has several limitations that bear mention. First, this was a small, cross-sectional study, limiting our ability to prospectively assess changes in cerebral vasoreactivity over time. Secondly, we lacked markers of systemic inflammation or immune activation obtained at the time of TCD with which to compare cerebrovascular function. Additionally, the overwhelming majority of our study participants were men, which reflects the general demographic make-up of the SCOPE cohort. Thus, we are not able to generalize our results to HIVinfected women. Given our data that the relative risk of stroke conferred by HIV infection in women is greater than men [3, 4] , studies aimed specifically at evaluating cerebrovascular function in women should be a top priority. Furthermore, use of one technologist in a single vascular laboratory precluded us from assessing interrater agreement for cerebral vasoreactivity, although data on interrater reliability of TCD-measured cerebral vasoreactivity are available [52] . Lastly, there were differences at baseline between the HIV-infected cohort and the uninfected control group, which may have affected the association between HIV status and cerebral vasoreactivity. However, the differences in cerebral vasoreactivity observed by HIV status persisted even after adjusting for these baseline differences.
The findings from this study advance our current knowledge of the impact of treated, virally suppressed HIV infection on vascular dysfunction by extending its negative effect to the cerebral vasculature. Importantly, these results provide one possible mechanism to explain increased cerebrovascular risk in HIV-infected individuals. Future studies should compare longitudinal changes in cerebrovascular function between HIV-infected individuals and uninfected controls, in addition to correlating markers of immune activation and inflammation with cerebrovascular function in HIV infection. Assessment of cerebral vasoreactivity has potential applications for use to identify individuals with cerebrovascular dysfunction at greater risk for stroke and to monitor response to interventions intended to reduce cerebrovascular risk in HIV infection.
